Clinical Trials Logo

Overactive Detrusor clinical trials

View clinical trials related to Overactive Detrusor.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05977634 Not yet recruiting - Overactive Bladder Clinical Trials

Transcutaneous Tibial Nerve Stimulation for Idiopathic Overactive Bladder

Start date: September 30, 2023
Phase: N/A
Study type: Interventional

This study was designed to assess the efficacy of trans cutaneous tibial nerve stimulation on symptoms of overactive bladder in women with idiopathic overactive bladder

NCT ID: NCT02009540 Not yet recruiting - Overactive Detrusor Clinical Trials

Botulinum Toxin in the Treatment of Idiopathic Detrusor Overactivity

Start date: December 2013
Phase: Phase 4
Study type: Interventional

Overactive Bladder (OAB) is a chronic condition caused by instability of the detrusor or bladder muscle, which gives rise to symptoms of urinary urgency and often urinary incontinence. Idiopathic Detrusor Overactivity (IDO) is a subset of OAB where the cause for the bladder muscle instability is unknown. OAB is usually treated by conservative measures or with oral medications eg. anticholinergics. Injection of onabotulinum toxin A (onaBoNT-A) into the bladder wall is licenced in the treatment of refractory IDO where oral medications fail. The injected toxin paralyses the bladder by blocking the ability of certain (motor) nerves to communicate with the bladder muscle. As these nerves are mainly concentrated in what is known as the "body" of the bladder this is traditionally where the injections are given. In addition to its action on motor nerves, onaBoNT-A also affects sensory nerve pathways. Recent studies show that IDO is caused by both motor and sensory nerve dysfunction, therefore injecting the "trigone", a part of the bladder where sensory nerves are particularly dense, may be of clinical benefit. Three studies comparing trigone versus trigone-sparing injection of botulinum toxin in the treatment of IDO have been carried out. One of these indicated a significant benefit in targeting the trigone and the other two did not show any difference. Our study aims to examine if injection of onaBoNT-A into the trigone alone will provide symptom and functional improvement in patients with IDO by comparing peritrigonal injection of onaBoNT-A with the traditional method of injection which spares the trigone.